^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    HOXA-AS2 (HOXA Cluster Antisense RNA 2)

    i
    Other names: HOXA-AS2, HOXA Cluster Antisense RNA 2, HOXA3as, HOXA Cluster Antisense RNA 2 (Non-Protein Coding), NONHSAG047182.2, NONHSAG047184.2, HSALNG0056854, HOXA-AS2
    Associations

    News

    Trials
    8ms
    Expression of Concern. (PubMed, Eur Rev Med Pharmacol Sci)
    Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway...PMID: 33577026. The Publisher apologizes for any inconvenience this may cause.
    Journal
    |
    IGF2 (Insulin-like growth factor 2) • MIR200B (MicroRNA 200b) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • FUS (FUS RNA Binding Protein) • TIMP2 (TIMP Metallopeptidase Inhibitor 2) • AFAP1-AS1 (AFAP1 Antisense RNA 1) • FOXO3 (Forkhead box O3) • PCNA (Proliferating cell nuclear antigen) • GAS5 (Growth Arrest Specific 5) • SMAD7 (SMAD Family Member 7) • DSCAM (DS Cell Adhesion Molecule) • HOXA-AS2 (HOXA Cluster Antisense RNA 2) • MIR29A (MicroRNA 29a) • MIR483 (MicroRNA 483) • MMP7 (Matrix metallopeptidase 7) • RBM24 (RNA Binding Motif Protein 24) • SNHG7 (Small Nucleolar RNA Host Gene 7) • TGFBR1 (Transforming Growth Factor Beta Receptor 1) • TGIF2 (TGFB Induced Factor Homeobox 2) • WTAP (WT1 Associated Protein) • XIST (X Inactive Specific Transcript) • MAGI2-AS3 (MAGI2 Antisense RNA 3)
    |
    cisplatin
    1year
    The functional role of LncRNA HOXA-AS2 in multiple human cancers. (PubMed, Pathol Res Pract)
    The regulatory mechanisms of HOXA-AS2 include inducing epithelial-mesenchymal transition (EMT), overexpressing B-cell lymphoma-2 (Bcl-2) and MYC proto-oncogene (c-Myc), gene silencing, activating AKT-MMP signaling pathways, EZH2 and LSD1, and functioning within a competing endogenous RNA (ceRNA) regulatory network by competitively binding miRNAs. This review surveys recent research on the structure, biological functions, abnormal expression, regulatory mechanisms, and diagnostic and therapeutic potential of HOXA-AS2 in various cancers.
    Review • Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • HOXA-AS2 (HOXA Cluster Antisense RNA 2)
    over1year
    Heterogeneous Transcriptional Landscapes in Human Sporadic Parathyroid Gland Tumors. (PubMed, Int J Mol Sci)
    In conclusion, PAds display heterogeneous transcriptomic profiles which may contribute to the modulation of clinical and biochemical features. The general downregulated gene expression, characterizing a subgroup of PAds, suggests the tumor cells behave as quiescent resting cells, while the severity of PHPT may be associated with the loss of p73 and the lncRNA-mediated deregulation of histones.
    Journal
    |
    CCND1 (Cyclin D1) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • TP73 (Tumor Protein P73) • CDC73 (Cell Division Cycle 73) • HOXA-AS2 (HOXA Cluster Antisense RNA 2)
    |
    CCND1 expression • CDKN1B expression
    over1year
    Clinicopathologic and prognostic implications of HOXA gene and its associated long-noncoding RNAs expression in non-small cell carcinoma: A meta-analysis. (PubMed, Medicine (Baltimore))
    The HOXA gene family has some potential to emerge as a novel prognostic factor for NSCLC and is correlated with some clinicopathological parameters such as the TNM stage, age and smoking. However, further meticulously designed prospective studies are warranted to substantiate these findings.
    Clinical • Retrospective data • Journal
    |
    HOXA11 (Homeobox A11) • HOTTIP (HOXA Distal Transcript Antisense RNA) • HOXA-AS2 (HOXA Cluster Antisense RNA 2)
    over1year
    LncRNA HOXA‑AS2 promotes the progression of epithelial ovarian cancer via the regulation of miR‑372. (PubMed, Oncol Lett)
    It was also demonstrated that the downregulation of miR-372 reversed the inhibitory effects of the knockdown of HOXA-AS2 in EOC cells. These results indicated that HOXA-AS2 promoted EOC progression by regulating the miR-372, which suggests that HOXA-AS2 may be a therapy target for EOC.
    Journal
    |
    HOXA-AS2 (HOXA Cluster Antisense RNA 2)
    almost2years
    HOXA-AS2 Epigenetically Inhibits HBV Transcription by Recruiting the MTA1-HDAC1/2 Deacetylase Complex to cccDNA Minichromosome. (PubMed, Adv Sci (Weinh))
    Mechanistically, HOXA-AS2 recruits the MTA1-HDAC1/2 deacetylase complex to cccDNA minichromosome by physically interacting with metastasis associated 1 (MTA1) subunit, resulting in reduced acetylation of histone H3 at lysine 9 (H3K9ac) and lysine 27 (H3K27ac) associated with cccDNA and subsequently suppressing cccDNA transcription. Altogether, the study reveals a mechanism to self-limit HBV replication, wherein the upregulation of lncRNA HOXA-AS2, induced by HBV DNA pol, can epigenetically suppress cccDNA transcription.
    Journal
    |
    HDAC1 (Histone Deacetylase 1) • HOXA-AS2 (HOXA Cluster Antisense RNA 2)
    almost2years
    LncRNA HOXA‑AS2 is a prognostic and clinicopathological predictor in patients with cancer: A meta‑analysis. (PubMed, Oncol Lett)
    However, the results of the present study also indicated that the expression of lncRNA HOXA-AS2 was not significantly associated with age or sex, suggesting its role in cancer progression might be independent of these factors. This insight may direct future research to place more focus on the relationship between lncRNA HOXA-AS2 and specific cancer types and clinical characteristics.
    Retrospective data • Journal
    |
    HOXA-AS2 (HOXA Cluster Antisense RNA 2)
    almost2years
    Helicobacter pylori infection induces gastric cancer cell malignancy by targeting HOXA-AS2/miR-509-3p/MMD2 axis. (PubMed, Genes Genomics)
    Hp infection induces the aggressiveness of GC cells by regulating HOXA-AS2/miR-509-3p/MMD2 axis.
    Journal
    |
    HOXA-AS2 (HOXA Cluster Antisense RNA 2) • MIR509-3 (MicroRNA 509-3)
    over2years
    A TGF-β signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response. (PubMed, CNS Neurosci Ther)
    A prognostic lncRNA signature of TGF-β signaling was established in glioma, which can be used for prognostic judgment, immune infiltration status inference, and immunotherapy response prediction. AGAP2-AS1 plays an important role in glioma progression.
    Journal • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1) • HOXA-AS2 (HOXA Cluster Antisense RNA 2) • HOXC13 (Homeobox C13)
    almost3years
    Identification and validation of fatty acid metabolism-related lncRNA signatures as a novel prognostic model for clear cell renal cell carcinoma. (PubMed, Sci Rep)
    Chemotherapeutic medications such lapatinib, AZD8055, and WIKI4 had better outcomes for patients in the high-risk group. Overall, the predictive signature can help with clinical selection of immunotherapeutic regimens and chemotherapeutic drugs, improving prognosis prediction for ccRCC patients.
    Journal • IO biomarker
    |
    HOXA-AS2 (HOXA Cluster Antisense RNA 2) • LINC01615 (Long Intergenic Non-Protein Coding RNA 1615)
    |
    lapatinib • AZD8055
    3years
    Construction of a Necroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Response in Kidney Renal Clear Cell Carcinoma. (PubMed, Cells)
    Furthermore, this signature based on the 6 NRLs could provide a promising method to predict the prognosis and immune response of KIRC patients. To some extent, our findings helped give a reference for further research between NRLs and KIRC and find more effective therapeutic drugs for KIRC.
    Journal
    |
    DLGAP1-AS2 (DLGAP1 Antisense RNA 2) • HOXA-AS2 (HOXA Cluster Antisense RNA 2) • LINC02100 (Long Intergenic Non-Protein Coding RNA 2100)
    3years
    Overexpression of lncRNA HOXA-AS2 promotes the progression of oral squamous cell carcinoma by mediating SNX5 expression. (PubMed, BMC Mol Cell Biol)
    HOXA-AS2 served an oncogene and promoted OSCC progression via the miR-520c-3p/SNX5 axis. Thus, HOXA-AS2 may be a new biomarker for diagnosis and treatment of OSCC.
    Journal
    |
    HOXA-AS2 (HOXA Cluster Antisense RNA 2)